Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Genmab ADR (NASDAQ: GMAB) closed the day trading at $20.26 down -7.80% from the previous closing price of $21.98. In other words, the price has decreased by -$7.80 from its previous closing price. On the day, 3.58 million shares were traded.
Ratios:
For a better understanding of GMAB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.64. For the most recent quarter (mrq), Quick Ratio is recorded 5.24 and its Current Ratio is at 5.25. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 13, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $27.
Valuation Measures:
As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.57, and their Forward P/E ratio for the next fiscal year is 11.37. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.13 while its Price-to-Book (P/B) ratio in mrq is 2.53.
Stock Price History:
Over the past 52 weeks, GMAB has reached a high of $31.88, while it has fallen to a 52-week low of $18.64. The 50-Day Moving Average of the stock is -4.68%, while the 200-Day Moving Average is calculated to be -15.66%.
Shares Statistics:
A total of 635.50M shares are outstanding, with a floating share count of 635.50M. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.61% stake in the company.
